Literature DB >> 22726545

Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.

Teru Hideshima1, Kenneth C Anderson.   

Abstract

The ubiquitin-proteasome pathway (UPP) is a major protein degradation system that maintains homeostasis of intracellular proteins, involved in DNA repair, cell cycle regulation, cell proliferation, and drug resistance. Since numerous proteins are processed by proteasomes, their inhibition triggers dramatic disruption of protein homeostasis. Consequently, accumulation of polyubiquitinated proteins triggers different types of cellular stress responses, followed by growth arrest and cytotoxicity. Importantly, multiple myeloma (MM) cells are considered to have lower threshold against these stresses than other cell types, which makes these cells sensitive to proteasome inhibitors.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22726545      PMCID: PMC3383768          DOI: 10.1053/j.seminhematol.2012.04.006

Source DB:  PubMed          Journal:  Semin Hematol        ISSN: 0037-1963            Impact factor:   3.851


  31 in total

Review 1.  Proteasome inhibitors: from research tools to drug candidates.

Authors:  A F Kisselev; A L Goldberg
Journal:  Chem Biol       Date:  2001-08

Review 2.  Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.

Authors:  Teru Hideshima; Paul G Richardson; Kenneth C Anderson
Journal:  Mol Cancer Ther       Date:  2011-11       Impact factor: 6.261

3.  Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia.

Authors:  Antonio Sacco; Monette Aujay; Brittany Morgan; Abdel Kareem Azab; Patricia Maiso; Yang Liu; Yong Zhang; Feda Azab; Hai T Ngo; Ghayas C Issa; Phong Quang; Aldo M Roccaro; Irene M Ghobrial
Journal:  Clin Cancer Res       Date:  2011-02-25       Impact factor: 12.531

4.  In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.

Authors:  Dharminder Chauhan; Ze Tian; Bin Zhou; Deborah Kuhn; Robert Orlowski; Noopur Raje; Paul Richardson; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2011-06-30       Impact factor: 12.531

5.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Authors:  T Hideshima; P Richardson; D Chauhan; V J Palombella; P J Elliott; J Adams; K C Anderson
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

6.  PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo.

Authors:  Ajita V Singh; Madhavi Bandi; Monette A Aujay; Christopher J Kirk; David E Hark; Noopur Raje; Dharminder Chauhan; Kenneth C Anderson
Journal:  Br J Haematol       Date:  2010-11-29       Impact factor: 6.998

7.  Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8.

Authors:  M A Laussmann; E Passante; H Düssmann; J A Rauen; M L Würstle; M E Delgado; M Devocelle; J H M Prehn; M Rehm
Journal:  Cell Death Differ       Date:  2011-04-01       Impact factor: 15.828

8.  NF-kappa B as a therapeutic target in multiple myeloma.

Authors:  Teru Hideshima; Dharminder Chauhan; Paul Richardson; Constantine Mitsiades; Nicholas Mitsiades; Toshiaki Hayashi; Nikhil Munshi; Lenny Dang; Alfredo Castro; Vito Palombella; Julian Adams; Kenneth C Anderson
Journal:  J Biol Chem       Date:  2002-02-28       Impact factor: 5.157

9.  Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.

Authors:  Teru Hideshima; Dharminder Chauhan; Tanyel Kiziltepe; Hiroshi Ikeda; Yutaka Okawa; Klaus Podar; Noopur Raje; Alexei Protopopov; Nikhil C Munshi; Paul G Richardson; Ruben D Carrasco; Kenneth C Anderson
Journal:  Blood       Date:  2009-03-06       Impact factor: 22.113

10.  Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

Authors:  Teru Hideshima; Hiroshi Ikeda; Dharminder Chauhan; Yutaka Okawa; Noopur Raje; Klaus Podar; Constantine Mitsiades; Nikhil C Munshi; Paul G Richardson; Ruben D Carrasco; Kenneth C Anderson
Journal:  Blood       Date:  2009-05-12       Impact factor: 22.113

View more
  12 in total

Review 1.  Nanotherapeutics for multiple myeloma.

Authors:  Alexander Zheleznyak; Monica Shokeen; Samuel Achilefu
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2018-04-26

Review 2.  Novel therapeutic strategies for multiple myeloma.

Authors:  Naoya Mimura; Teru Hideshima; Kenneth C Anderson
Journal:  Exp Hematol       Date:  2015-06-26       Impact factor: 3.084

3.  MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma.

Authors:  Qiang Wang; Dongyu Zhao; Miao Xian; Zhuo Wang; Enguang Bi; Pan Su; Jianfei Qian; Xingzhe Ma; Maojie Yang; Lintao Liu; Youli Zu; Sai Ravi Pingali; Kaifu Chen; Zhen Cai; Qing Yi
Journal:  Blood       Date:  2020-11-26       Impact factor: 22.113

Review 4.  The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.

Authors:  Claudia V Andreu-Vieyra; James R Berenson
Journal:  Ther Adv Hematol       Date:  2014-12

Review 5.  When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response.

Authors:  Shardule P Shah; Sagar Lonial; Lawrence H Boise
Journal:  Mol Cancer Res       Date:  2015-05-26       Impact factor: 5.852

6.  Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling.

Authors:  Xing-Ding Zhang; Veerabhadran Baladandayuthapani; Heather Lin; George Mulligan; Bin Li; Dixie-Lee W Esseltine; Lin Qi; Jianliang Xu; Walter Hunziker; Bart Barlogie; Saad Z Usmani; Qing Zhang; John Crowley; Antje Hoering; Jatin J Shah; Donna M Weber; Elisabet E Manasanch; Sheeba K Thomas; Bing-Zong Li; Hui-Han Wang; Jiexin Zhang; Isere Kuiatse; Jin-Le Tang; Hua Wang; Jin He; Jing Yang; Enrico Milan; Simone Cenci; Wen-Cai Ma; Zhi-Qiang Wang; Richard Eric Davis; Lin Yang; Robert Z Orlowski
Journal:  Cancer Cell       Date:  2016-04-28       Impact factor: 31.743

7.  Multiple myeloma cells are exceptionally sensitive to heat shock, which overwhelms their proteostasis network and induces apoptosis.

Authors:  Zhe Sha; Alfred L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-19       Impact factor: 11.205

8.  A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.

Authors:  Enrico Milan; Tommaso Perini; Massimo Resnati; Ugo Orfanelli; Laura Oliva; Andrea Raimondi; Paolo Cascio; Angela Bachi; Magda Marcatti; Fabio Ciceri; Simone Cenci
Journal:  Autophagy       Date:  2015       Impact factor: 16.016

Review 9.  Autophagy in plasma cell pathophysiology.

Authors:  Laura Oliva; Simone Cenci
Journal:  Front Immunol       Date:  2014-03-12       Impact factor: 7.561

10.  Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.

Authors:  Fulvia Cerruti; Genny Jocollè; Chiara Salio; Laura Oliva; Luca Paglietti; Beatrice Alessandria; Silvia Mioletti; Giovanni Donati; Gianmauro Numico; Simone Cenci; Paolo Cascio
Journal:  Sci Rep       Date:  2017-12-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.